Second Sight Medical Products Inc. (EYES) Trading Down 3.1%
Second Sight Medical Products Inc. (NASDAQ:EYES) shares fell 3.1% during mid-day trading on Tuesday . The company traded as low as $3.79 and last traded at $3.79, with a volume of 67,836 shares changing hands. The stock had previously closed at $3.91.
A number of brokerages have issued reports on EYES. Zacks Investment Research raised Second Sight Medical Products from a “sell” rating to a “hold” rating in a report on Thursday, May 19th. Rodman & Renshaw reissued a “buy” rating and set a $16.00 price objective on shares of Second Sight Medical Products in a report on Tuesday, July 26th.
The stock’s 50-day moving average price is $3.95 and its 200-day moving average price is $4.43. The firm’s market capitalization is $157.40 million.
Second Sight Medical Products (NASDAQ:EYES) last posted its quarterly earnings results on Thursday, July 28th. The medical device company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by $0.02. The company earned $1.04 million during the quarter, compared to analyst estimates of $2.66 million. During the same quarter in the previous year, the business posted ($0.12) EPS. The company’s revenue for the quarter was down 63.0% compared to the same quarter last year. Equities analysts predict that Second Sight Medical Products Inc. will post ($0.62) EPS for the current fiscal year.
In related news, Chairman Robert J. Greenberg sold 8,571 shares of the stock in a transaction on Thursday, June 2nd. The stock was sold at an average price of $4.10, for a total value of $35,141.10. Following the sale, the chairman now owns 172,911 shares in the company, valued at approximately $708,935.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.